Esketamine for depression: all studies (page 10)

Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine.

International journal of psychiatry in clinical practice April 29, 2026 David Eckert, Siegfried Kasper

The treatment of treatment-resistant depression (TRD) remains a clinical challenge. Pharmacologically, several augmentation options exist. The aim of this study was to present a mechanistically informed and clinically oriented decision-making framework for the established strategies of lithium, quetiapine, and esketamine. We conducted a narrative, non-systematic review, performing a targeted...

DOI: 10.1080/13651501.2026.2663307 Full text Esketamine Treatment-resistant depression trd Lithium Pharmacological augmentation +1

Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series.

BMC Psychiatry April 26, 2026 Sergi López-rodríguez, Cinto Segalàs, Eva Real et al.

BACKGROUND: Patients with obsessive–compulsive disorder (OCD) and comorbid major depressive disorder (MDD) represent a severe subgroup with increased treatment resistance, greater functional impairment, and limited therapeutic options. Intranasal esketamine is a rapidly acting treatment for resistant depression, with emerging interest in potential anti-obsessional effects. However, prospective...

DOI: 10.1186/s12888-026-08119-5 Full text Major depressive disorder Comorbidity Intranasal esketamine Obsessive–compulsive disorder +2

Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression.

Journal of psychopharmacology (Oxford, England) April 24, 2026 Marco Colizzi, Elisa Morandin, Veronica Croccia et al.

Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...

DOI: 10.1177/02698811261443676 Full text Esketamine Treatment-resistant depression Biological predictors Glutamatergic system +4

Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial.

Scientific Reports April 21, 2026 Rong Ding, Daojie Wang, Guoxin Wang et al.

Elderly colorectal cancer (CRC) patients face high risks of postoperative depression state, inadequately addressed by opioid-based analgesia. Esketamine, an NMDA receptor antagonist with rapid antidepressant effects, offers potential benefits but lacks evidence in this population. This double-blind RCT enrolled 99 elderly (≥ 65 years) CRC resection patients, randomized to three postoperative...

DOI: 10.1038/s41598-026-49287-4 Full text Esketamine Colorectal cancer Elderly Patient-controlled analgesia +1

A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

Journal of Affective Disorders April 15, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al. 4 citations

Ketamine and esketamine exhibit rapid antidepressant effects in persons with treatment-resistant depression (TRD) and bipolar depression (TRBD). However, the synaptic mechanisms governing dose, frequency, and durability of response remain unclear. This review aims to evaluate the dosing parameters, including minimum dose and optimal dosing intervals, that reliably induce or maintain long-term...

DOI: 10.1016/j.jad.2025.121081 Full text Depressive disorder Ketamine Drug administration schedule Long-term potentiation +2

Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation.

Journal of Affective Disorders April 15, 2026 Jen-Ping Chen, Chih-Wei Hsu, Yi-Ting Chen et al.

Repetitive transcranial magnetic stimulation (rTMS) and esketamine are FDA-approved treatments for treatment-resistant depression (TRD), yet head-to-head comparative effectiveness data remain limited. Our study compared the effectiveness and safety profiles of rTMS versus esketamine in adults with TRD. This cohort study used target trial emulation with 1:1 propensity score matching on 50...

DOI: 10.1016/j.jad.2025.121132 Full text Esketamine Treatment-resistant depression Target trial emulation

Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.

Translational Psychiatry April 10, 2026 Ting-Hui Liu, Hong-Shiang Shen, Jheng-Yan Wu et al. 1 citation

This study aimed to evaluate the long-term effectiveness and safety of esketamine in adults with Major depressive disorder (MDD), focusing on suicide-related events, all-cause mortality, and major adverse cardiovascular events (MACEs). This target-trial simulation used the TriNetX Global Collaborative Network. Adults (≥ 18 years) with MDD who received either esketamine or a conventional...

DOI: 10.1038/s41398-026-04032-3 Full text Ketamine Major depressive disorder Humans Antidepressive agents +5

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intranasal Esketamine for Rapid Symptom Relief in Treatment-resistant Depression.

Reviews on recent clinical trials April 7, 2026 Ritika Saun, Aakriti Garg, Mohd Ashif Khan

Most of the Major Depressive Disorder (MDD) patients experience Treatment-Resistant Depression (TRD), wherein standard pharmaceutical and psychological interventions fail to provide adequate symptom relief. This systematic review and meta-analysis investigated the efficacy and safety of intranasal esketamine for rapid symptom relief in adults with TRD. The search strategy adhered to PRISMA...

DOI: 10.2174/0115748871407261251215071206 Full text Mdd Esketamine Major depressive disorder Severe depression +2

Esketamine prevents postpartum depression after cesarean section: a Meta-analysis

Yixue xinzhi zazhi April 2, 2026 Yao Wenzhuang, Zhang Hanyun, Liu Suman et al.

Objective To systematically evaluate the efficacy and safety of Esketamine on postpartum depression (PPD) in cesarean section women.Methods Databases including PubMed, Embase, Web of Science, The Cochrane Library, CBM, CNKI, WanFang and VIP were searched from inception to March 2025 for RCTs investigating the impact of Esketamine on PPD in cesarean section parturients. RevMan 5.4 and Stata 18.0...

DOI: 10.12173/j.issn.1004-5511.202505094 Full text Esketamine Cesarean section Postpartum depression Patient-controlled intravenous analgesia +1

Metabolomic Profiling of Extracellular Vesicles Reveals Distinct Metabolic Dysregulation and Treatment-Specific Signatures in Depression.

Biomolecules April 2, 2026 Nikola Balic, Gordana Nedic Erjavec, Marcela Konjevod et al.

Major depressive disorder (MDD) is associated with complex metabolic alterations. In this study, we applied a multiplatform metabolomics approach (GC-MS and LC-MS) to characterize the plasma extracellular vesicle (EV) metabolome in healthy controls (N = 50), responsive MDD patients (N = 60), and patients with treatment-resistant depression (TRD; N = 65). Longitudinal analyses were performed...

DOI: 10.3390/biom16040533 Full text Mdd Esketamine Trd Bright-light therapy +4

Research